Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review
- PMID: 25114574
- PMCID: PMC4125372
- DOI: 10.2147/OTT.S65774
Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review
Abstract
Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.
Keywords: CDDP; PTX; chemotherapy; cytotoxic drugs; oncology.
Figures
References
-
- Ziske CG, Schöttker B, Gorschlüter M, et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol. 2002;13(4):629–631. - PubMed
-
- Cavaletti G, Bogliun G, Marzorati L, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75(5):1141–1150. - PubMed
-
- Anand A, Huberman M. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;76(5):916–917. - PubMed
-
- Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol. 2006;141(1):196–197. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
